Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021
Open Access
- 27 July 2023
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (30) , 2200837-23
Abstract
Background: Georgia has adopted the World Health Organization European Region’s and global goals to eliminate viral hepatitis. A nationwide serosurvey among adults in 2015 showed 2.9% prevalence for hepatitis B virus (HBV) surface antigen (HBsAg) and 25.9% for antibodies against HBV core antigen (anti-HBc). HBV infection prevalence among children had previously not been assessed. Aim: We aimed to assess HBV infection prevalence among children and update estimates for adults in Georgia. Methods: This nationwide cross-sectional serosurvey conducted in 2021 among persons aged ≥ 5 years used multi-stage stratified cluster design. Participants aged 5–20 years were eligible for hepatitis B vaccination as infants. Blood samples were tested for anti-HBc and, if positive, for HBsAg. Weighted proportions and 95% confidence intervals (CI) were calculated for both markers. Results: Among 5–17 year-olds (n = 1,473), 0.03% (95% CI: 0–0.19) were HBsAg-positive and 0.7% (95% CI: 0.3–1.6) were anti-HBc-positive. Among adults (n = 7,237), 2.7% (95% CI: 2.3–3.4) were HBsAg-positive and 21.7% (95% CI: 20.4–23.2) anti-HBc-positive; HBsAg prevalence was lowest (0.2%; 95% CI: 0.0–1.5) among 18–23-year-olds and highest (8.6%; 95% CI: 6.1–12.1) among 35–39-year-olds. Conclusions: Hepatitis B vaccination in Georgia had remarkable impact. In 2021, HBsAg prevalence among children was well below the 0.5% hepatitis B control target of the European Region and met the ≤ 0.1% HBsAg seroprevalence target for elimination of mother-to-child transmission of HBV. Chronic HBV infection remains a problem among adults born before vaccine introduction. Screening, treatment and preventive interventions among adults, and sustained high immunisation coverage among children, can help eliminate hepatitis B in Georgia by 2030.Keywords
This publication has 28 references indexed in Scilit:
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling studyThe Lancet Gastroenterology & Hepatology, 2018
- Hepatitis B vaccines: WHO position paper – July 2017.2017
- Proceedings of The 8th Romanian National HIV/AIDS Congress and The 3rd Central European HIV ForumBMC Infectious Diseases, 2016
- Substantial decline in hepatitis B virus infections following vaccine introduction in TajikistanVaccine, 2015
- Hepatitis C among people who inject drugs in Tbilisi, Georgia: An urgent need for prevention and treatmentInternational Journal of Drug Policy, 2014
- Die Seroepidemiologie der Hepatitis A, B und C in DeutschlandBundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2013
- Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicityVaccine, 2012
- Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patientsInternational Journal of Infectious Diseases, 2008
- A mathematical model to estimate global hepatitis B disease burden and vaccination impactInternational Journal of Epidemiology, 2005
- Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donorsEuropean Journal of Epidemiology, 2001